Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 308

The DOI matches its Crossref record; 175 of the 175 references it cites were found in a registry or an index.

European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023

Open access
Peris, Ketty, Fargnoli, Maria Concetta, Kaufmann, Roland, Arenberger, Petr, Bastholt, Lars, Seguin, Nicole Basset, Bataille, Veronique, Brochez, Lieve, del Marmol, Veronique, Dummer, Reinhard, Forsea, Ana-Marie, Gaudy-Marqueste, Caroline, Harwood, Catherine A., Hauschild, Axel, Höller, Christoph, Kandolf, Lidija, Kellerners-Smeets, Nicole W.J., Lallas, Aimilios, Leiter, Ulrike, Malvehy, Josep, Marinović, Branka, Mijuskovic, Zeljko, Moreno-Ramirez, David, Nagore, Eduardo, Nathan, Paul, Stratigos, Alexander J., Stockfleth, Eggert, Tagliaferri, Luca, Trakatelli, Myrto, Vieira, Ricardo, Zalaudek, Iris, Garbe, Claus·2023·European Journal of Cancer
DOI 10.1016/j.ejca.2023.113254
Open this paper in CoChat — free account

Abstract

Basal cell carcinoma (BCC) is the most common malignant tumour in white populations. Multidisciplinary experts from European Association of Dermato-Oncology (EADO), European Dermatology Forum, European Society for Radiotherapy and Oncology (ESTRO), Union Européenne des Médecins Spécialistes, and the European Academy of Dermatology and Venereology developed updated recommendations on diagnosis and treatment of BCC. BCCs were categorised into 'easy-to-treat' (common) and 'difficult-to-treat' according to the new EADO clinical classification. Diagnosis is based on clinico-dermatoscopic features, although histopathological confirmation is mandatory in equivocal lesions. The first-line treatment of BCC is complete surgery. Micrographically controlled surgery shall be offered in high-risk and recurrent BCC, and BCC located on critical anatomical sites. Topical therapies and destructive approaches can be considered in patients with low-risk superficial BCC. Photodynamic therapy is an effective treatment for superficial and low-risk nodular BCCs. Management of 'difficult-to-treat' BCCs should be discussed by a multidisciplinary tumour board. Hedgehog inhibitors (HHIs), vismodegib or sonidegib, should be offered to patients with locally advanced and metastatic BCC. Immunotherapy with anti-PD1 antibodies (cemiplimab) is a second-line treatment in patients with a progression of disease, contraindication, or intolerance to HHI therapy. Radiotherapy represents a valid alternative in patients who are not candidates for or decline surgery, especially elderly patients. Electrochemotherapy may be offered when surgery or radiotherapy is contraindicated. In Gorlin patients, regular skin examinations are required to diagnose and treat BCCs at an early stage. Long-term follow-up is recommended in patients with high-risk BCC, multiple BCCs, and Gorlin syndrome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejca.2023.113254

Cites

175 of 175 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 308

Metadata

Authors
Peris, K., Fargnoli, M. C., Kaufmann, R., Arenberger, P., Bastholt, L., Seguin, N. B., Bataille, V., Brochez, L., del Marmol, V., Dummer, R., Forsea, A.-M., Gaudy-Marqueste, C., Harwood, C. A., Hauschild, A., Höller, C., Kandolf, L., Kellerners-Smeets, N. W. J., Lallas, A., Leiter, U., Malvehy, J., Marinović, B., Mijuskovic, Z., Moreno-Ramirez, D., Nagore, E., Nathan, P., Stratigos, A. J., Stockfleth, E., Tagliaferri, L., Trakatelli, M., Vieira, R., Zalaudek, I., & Garbe, C.
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
2023-10
Volume
192
Pages
113254
ISSN
0959-8049 (ISSN-L)
DOI
10.1016/j.ejca.2023.113254
OpenAlex
W4385336092
Cited by
308
References
175
FWCI
51.51
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.